import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'gcc-immunology-biologics-market-report';

/**
 * Curated copy for the GCC immunology & biologics programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry).
 * Epidemiology where cited: EAACI / published prevalence ranges as noted in therapy enrichment.
 */
type GccImmunologyOverride = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const GCC_IMMUNOLOGY_BIOLOGICS_COPY: GccImmunologyOverride = {
  slug: SLUG,
  title: 'GCC Immunology & Biologics Market Report 2026',
  metaTitle: 'GCC Biologics Market Report 2026 | Immunology & Middle East Biologics | BioNixus',
  metaDescription:
    'GCC biologics market ~$5.9B in 2026 (BioNixus analysis)—Middle East immunology & biologics: SFDA & MOHAP pathways, NUPCO tenders, biosimilar switching, IL-17/IL-23 & JAK access—Gulf intelligence.',
  heroLead:
    'This briefing sizes the Gulf immunology and biologics opportunity with account-level realism: where hospital tenders reset net price, where insurer step therapy gates oral JAKs, and where rheumatology, dermatology, and gastroenterology boards actually sequence TNF, IL-17, IL-23, and IL-4Rα therapy.',
  summaryPara1:
    'Gulf immunology and biologics spend in 2026 is concentrated in Saudi Arabia and the United Arab Emirates, with Kuwait, Qatar, Bahrain, and Oman contributing smaller but structurally distinct tender and insurance cells. BioNixus estimates the six-market addressable market at roughly USD 5.9 billion in 2026, advancing toward about USD 9.7 billion by 2030 at approximately 12.6% CAGR—driven less by headline incidence than by biologic and biosimilar volume, prior-authorization depth, and infusion-centre capacity in public and private channels. Country splits and therapy-class detail below reflect BioNixus market analysis, 2026, not unaudited third-party panel extrapolation alone.',
  summaryPara2:
    'Use this report alongside the [GCC pharmaceutical market report 2026](/gcc-pharma-market-report-2026) for macro sizing, the [GCC biosimilars market report](/market-reports/gcc-biosimilars-market-report) for tender-led substitution, [immunology therapy research](/healthcare-market-research/therapy/immunology) and [biologics therapy research](/healthcare-market-research/therapy/biologics) for programme design, the [SFDA market access strategy for Saudi Arabia](/sfda-market-access-strategy-saudi-arabia) when KSA listing is on your critical path, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork across the Gulf.',
  marketAccessNotes:
    'Priority access signals for 2026: adalimumab and other anti-TNF biosimilar waves in Saudi NUPCO-led hospital tenders; emirate-level prior-authorization stacks for IL-17 and IL-23 agents in UAE mandatory insurance products; specialist-only JAK prescribing with cardiovascular and malignancy vigilance requirements aligned to FDA and EMA label warnings; IL-4Rα (dupilumab) growth in atopic dermatitis and asthma where SFDA and MOHAP labels are active; infusion-chair throughput and TB screening logistics that delay first biologic starts outside capital-city clusters.',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat Gulf immunology as a network of chronic decisions—not a single specialty map. Rheumatologists, dermatologists, and gastroenterologists often share the same biologic budget line, while nurses operationalise infusions, pharmacists manage cold chain and substitution rules, and payer medical directors interpret step-therapy language that differs between Thiqa-style benefits in Abu Dhabi, mandatory Dubai products, and MOH hospital formularies in Riyadh or Jeddah. We pair hospital procurement signals (where clients share them) with bilingual physician quantitative work and payer qualitative depth so brand, medical, and access teams see whether hesitation is clinical, operational, or economic. Treat-to-target indices such as DAS28 or CDAI appear in charts, but adoption forecasts only hold when TB screening completion, Ramadan fasting counselling for oral switches, and Friday prayer scheduling around infusion suites are captured in the same study—not assumed from EU analogues.',
  commercialOutlookParagraph:
    'Commercial outlook through 2030 remains constructive for manufacturers that segment by channel: tender-led MOH and NGHA accounts in Saudi Arabia versus premium insured networks in the UAE, with Kuwait and Qatar adding smaller but high per-capita rheumatology and dermatology pockets. Biosimilar awards will continue to compress net price on mature anti-TNF classes; originators defend with device experience, indication breadth, and patient-support operations that insurers increasingly expect to see documented. IL-17 and IL-23 competition in psoriasis and psoriatic arthritis will intensify as formularies tighten; JAK inhibitors will grow where oral convenience wins but face insurer medical-policy friction after global safety communications. Leadership should stress-test share assumptions by account archetype—NUPCO-aligned hospital, private infusion centre, and mixed insurer panel—before locking regional revenue targets.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands, structured desk review of SFDA, MOHAP, DHA, DOH, and peer Gulf authority public guidance, and primary research modules (physician adoption surveys, payer policy interviews, tender post-mortems where available). Epidemiology references use published ranges—for example, atopic dermatitis prevalence among children in parts of the Gulf has been reported among the higher global bands in EAACI-aligned literature; rheumatoid arthritis and psoriasis prevalence estimates in regional summaries are applied as planning inputs, not as patient-level forecasts. All policy and formulary statements should be revalidated before launch decisions because Gulf insurers and hospital committees update medical policies on short cycles. Outputs are intended for market access, medical affairs, and commercial leadership; they do not constitute regulatory or legal advice.',
  faqs: [
    {
      question: 'How large is the GCC immunology and biologics market in 2026?',
      answer:
        'BioNixus market analysis sizes the six GCC markets at approximately USD 5.9 billion in 2026 for immunology and biologics combined, with a trajectory toward roughly USD 9.7 billion by 2030 at about 12.6% CAGR. Saudi Arabia contributes the largest share of spend; the UAE is the second-largest market and the fastest-moving private-insurance environment. Kuwait, Qatar, Bahrain, and Oman are smaller in absolute dollars but can be decisive for niche biologic launches because tender and insurance rules differ from Riyadh or Dubai templates. Use the GCC pharmaceutical market report 2026 for macro pharma context and country therapy reports for KSA and UAE drill-down.',
    },
    {
      question: 'How are biologics and immunology medicines regulated across the GCC?',
      answer:
        'Each member state maintains its own marketing authorisation authority: SFDA in Saudi Arabia; MOHAP federally in the UAE with additional emirate requirements from DHA (Dubai) and DOH (Abu Dhabi) where products are used in licensed facilities; and MOH or NHRA equivalents in Kuwait, Qatar, Bahrain, and Oman. Biologics generally follow ICH-aligned dossier expectations with Gulf-specific labelling, pharmacovigilance, and cold-chain evidence. Biosimilar pathways exist in Saudi Arabia and the UAE; interchangeability and substitution rules are interpreted at hospital and insurer level, not only at registration. Teams should map the exact sequence—SFDA or MOHAP approval first, then hospital formulary, then insurer medical policy—for each target account.',
    },
    {
      question: 'How does reimbursement and hospital procurement work for immunology biologics in the Gulf?',
      answer:
        'Saudi Arabia channels a large share of hospital biologic volume through NUPCO and related MOH and NGHA procurement, where tender outcomes can reset adalimumab and other anti-TNF net prices across many facilities at once. The UAE splits between MOHAP-listed products, DHA and DOH hospital decisions, and mandatory insurance prior authorization that varies by product class—IL-17 and IL-23 agents often face step therapy after conventional systemic therapy, while JAK inhibitors frequently require specialist prescribing and safety monitoring documentation. Kuwait, Qatar, and Bahrain rely heavily on central medical stores or corporation tenders with high generic and biosimilar substitution pressure in public channels. Infusion capacity, nurse training, and TB screening workflows often determine real-world uptake as much as formulary listing.',
    },
    {
      question: 'Which drug classes are reshaping GCC immunology prescribing in 2026?',
      answer:
        'Anti-TNF agents (adalimumab, etanercept, infliximab and biosimilars) remain high-volume but face biosimilar tender pressure in Saudi hospital channels. IL-17 and IL-23 inhibitors (secukinumab, ixekizumab, guselkumab, risankizumab) compete in psoriasis, psoriatic arthritis, and axial spondyloarthritis with payer prior-authorization tiers that differ by emirate and insurer in the UAE. IL-4Rα blockade with dupilumab is a major growth driver in atopic dermatitis and moderate-to-severe asthma where SFDA and MOHAP labels are active; published allergy literature has reported high atopic dermatitis burden among children in parts of the Gulf, which supports demand but still requires local chart verification. JAK inhibitors (upadacitinib, tofacitinib, baricitinib) offer oral convenience but trigger insurer scrutiny because FDA and EMA labels carry boxed warnings on serious infections, malignancy, thrombosis, and major adverse cardiovascular events—language that Gulf medical policies often mirror. Gastroenterology biologics (vedolizumab, ustekinumab, infliximab) tie adoption to infusion-centre capacity and IBD referral depth, especially where gastroenterology waitlists gate first biologic eligibility.',
    },
    {
      question: 'What operational factors delay biologic adoption in GCC hospitals and clinics?',
      answer:
        'Teams consistently underestimate non-clinical friction: latent tuberculosis screening and treatment delays before anti-TNF or IL-17 initiation; infusion chair scheduling around Friday congregations and Ramadan fasting counselling for patients switching to oral JAKs; cold-chain breaks when products travel to hospitals outside capital corridors; and dual documentation burdens when both hospital pharmacy and insurer medical policy must approve the same patient. Heat-related skin disease flares can accelerate dermatology biologic starts in summer months, but payer resets at calendar year or policy renewal can stall continuation. Nurse-led infusion training turnover, pharmacist substitution mandates after tender awards, and incomplete electronic medical record documentation for treat-to-target scores further distort claims-based analytics. BioNixus recommends mapping these operational gates in qualitative work alongside quantitative prescribing surveys so launch and access plans reflect bedside reality, not formulary status alone.',
    },
    {
      question: 'How does BioNixus help pharmaceutical teams win in GCC immunology and biologics?',
      answer:
        'BioNixus designs bilingual (Arabic–English) programmes across Saudi Arabia, the UAE, Kuwait, Qatar, Bahrain, and Oman: rheumatology, dermatology, and gastroenterology physician adoption studies; payer and medical-policy interviews; biosimilar confidence and substitution simulations; tender intelligence for hospital accounts; and KOL mapping tied to real referral pathways rather than title lists. We align deliverables to launch, biosimilar defense, or indication expansion milestones, and we connect Gulf findings to global benchmarks only when a comparator market truly informs your governance narrative. Typical outputs include segment dossiers, objection libraries, access risk maps, and executive summaries suitable for regional brand and access committees. Request a scoped briefing through the contact page or begin from the healthcare market research hub to review country, therapy, and macro report entry points before fieldwork starts.',
    },
  ],
};

export function applyGccImmunologyBiologicsCopyOverride(entries: ReportEntry[]): ReportEntry[] {
  return entries.map((entry) => {
    if (entry.slug !== SLUG) return entry;
    const { slug: _slug, ...patch } = GCC_IMMUNOLOGY_BIOLOGICS_COPY;
    return { ...entry, ...patch };
  });
}
